[ET Net News Agency, 29 November 2019] China Resources Pharmaceutical Group Limited
(03320) said its biopharmaceutical drug, Rui Tong Li (commonly known as "Reteplase",
Reteplase (rPA) for InJection) has undergone evaluation for inclusion in the 2019 National
Reimbursement Drug List (NRDL) with assessment of a high pharmacoeconomic value resulting
in inclusion within the list.
Rui Tong Li is produced by China Resources AngDe Biotech Pharma Co., Ltd, a controlling
subsidiary of the group's biopharmaceutical platform. The drug is used to treat acute
myocardial infarction, effectively reducing the mortality rate, and aiding patient
recovery.
Rui Tong Li is the first third-generation specific thrombolytic agent launched in China,
and the only one included in the 2018 National Essential Medicine List among all specific
thrombolytic agents due to its outstanding clinical results.
Rui Tong Li recorded an annual turnover of RMB50 million in 2018, occupying around 3.5%
of the market of thrombolytic products. In the future, relying on policy support from
being included in the National Essential Medicines List and the NRDL, combining with the
product's comprehensive clinical efficacy and price advantages, the group expects that the
annual sales of Rui Tong Li will be likely to exceed RMB200 million. (KL)